Macrophages
FDA grants rare pediatric disease designation to treatment for systemic JIA flares
The FDA has granted rare pediatric disease designation to a type IA prodrug of dexamethasone that targets CD206+ macrophages for the treatment of systemic juvenile idiopathic arthritis flares, according to a press release from PIF Partners.
VIDEO: AVD-104 shows encouraging results in phase 2/3 study
In this video, Rishi P. Singh, MD, discusses results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy, presented at the ASRS annual meeting in Stockholm.
VIDEO: Choroidal macrophages could be target for AMD treatments
SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, continues to discuss highlights from the ARVO annual meeting.
Itaconate derivative provides new approach to target JAK1 in potential asthma treatment
Itaconate and its derivative 4-octyl itaconate inhibit the Januse kinase 1 immune protein, which has implications for potential severe asthma treatment, according to a study published in Cell Metabolism.